Turning Science Into
SynDevRx, Inc. (“SDX”) based in Cambridge, Massachusetts, is
developing new and effective treatments for cancer patients and serious metabolic-related diseases using our patented polymer-drug conjugates.
Our lead compound - SDX-7320 - in Phase 1 for oncology, is a best-in-class MetAP2 inhibitor conjugated to a bio-compatible polymer
which releases the pharmacologically active small molecule in vivo. Our polymer conjugation approach reduces systemic drug
exposure compared to the small molecule drug alone. The expected
clinical consequence of lowering systemic exposure is an improved
safety profile. Our proprietary polymer conjugation
chemistry keeps the active drug inert while in general circulation thereby
greatly reducing systemic toxicities. SDX-7320
exhibits significantly lower Cmax and a much longer half-life than small molecules, which allows
for less frequent dosing schedules.
models, SDX-7320 has shown improved activity and safety relative to small molecule
compounds from the fumagillin class.
SDX clinical development program targets solid tumors as well as serious metabolic-related diseases. Our compounds inhibit MetAP2 - an enzyme which
independent research has shown to be important in the regulation of a
number of cellular processes including cell proliferation, lipid processing, angiogenesis and protein turnover.
compound is currently in development and is not approved by the FDA (or
any other regulatory authority) for clinical use.
SynDevRx is a registered trademark of SynDevRx, Inc.